guest ::
| Home > Publications Database > A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease. > print |
| Home > Publications Database > A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease. > print |
| 001 | 155632 | ||
| 005 | 20230915092333.0 | ||
| 024 | 7 | _ | |a 10.1002/mds.28534 |2 doi |
| 024 | 7 | _ | |a pmid:33617693 |2 pmid |
| 024 | 7 | _ | |a 0885-3185 |2 ISSN |
| 024 | 7 | _ | |a 1531-8257 |2 ISSN |
| 024 | 7 | _ | |a altmetric:100652704 |2 altmetric |
| 037 | _ | _ | |a DZNE-2021-00800 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Liu, Hui |0 P:(DE-2719)9001971 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease. |
| 260 | _ | _ | |a New York, NY |c 2021 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1683798430_30879 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The SNCA gene encoding α-synuclein (αSyn) is the first gene identified to cause autosomal-dominant Parkinson's disease (PD).We report the identification of a novel heterozygous A30G mutation of the SNCA gene in familial PD and describe clinical features of affected patients, genetic findings, and functional consequences.Whole exome sequencing was performed in the discovery family proband. Restriction digestion with Bbvl was used to screen SNCA A30G in two validation cohorts. The Greek cohort included 177 familial PD probands, 109 sporadic PD cases, and 377 neurologically healthy controls. The German cohort included 136 familial PD probands, 380 sporadic PD cases, and 116 neurologically healthy controls. We also conducted haplotype analysis using 13 common single nucleotide variants around A30G to determine the possibility of a founder effect for A30G. We then used biophysical methods to characterize A30G αSyn.We identified a novel SNCA A30G (GRCh37, Chr4:90756730, c.89 C>G) mutation that co-segregated with the disease in five affected individuals of three Greek families and was absent from controls. A founder effect was strongly suggested by haplotype analysis. The A30G mutation had a local effect on the intrinsically disordered structure of αSyn, slightly perturbed membrane binding, and promoted fibril formation.Based on the identification of A30G co-segregating with the disease in three families, the absence of the mutation in controls and population databases, and the observed functional effects, we propose SNCA A30G as a novel causative mutation for familial PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a A30G |2 Other |
| 650 | _ | 7 | |a Parkinsonʼs disease |2 Other |
| 650 | _ | 7 | |a SNCA |2 Other |
| 650 | _ | 7 | |a SNCA protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a alpha-Synuclein |2 NLM Chemicals |
| 650 | _ | 2 | |a Founder Effect |2 MeSH |
| 650 | _ | 2 | |a Greece |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Mutation: genetics |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a alpha-Synuclein: genetics |2 MeSH |
| 700 | 1 | _ | |a Koros, Christos |b 1 |
| 700 | 1 | _ | |a Strohäker, Timo |0 P:(DE-2719)2812850 |b 2 |
| 700 | 1 | _ | |a Schulte, Claudia |0 P:(DE-2719)9000366 |b 3 |
| 700 | 1 | _ | |a Bozi, Maria |b 4 |
| 700 | 1 | _ | |a Varvaresos, Stefanos |b 5 |
| 700 | 1 | _ | |a Ibáñez de Opakua, Alain |0 P:(DE-2719)2812657 |b 6 |
| 700 | 1 | _ | |a Simitsi, Athina Maria |b 7 |
| 700 | 1 | _ | |a Bougea, Anastasia |0 0000-0003-3006-8711 |b 8 |
| 700 | 1 | _ | |a Voumvourakis, Konstantinos |b 9 |
| 700 | 1 | _ | |a Maniati, Matina |b 10 |
| 700 | 1 | _ | |a Papageorgiou, Sokratis G |b 11 |
| 700 | 1 | _ | |a Hauser, Ann-Kathrin |0 P:(DE-2719)2351249 |b 12 |
| 700 | 1 | _ | |a Becker, Stefan |b 13 |
| 700 | 1 | _ | |a Zweckstetter, Markus |0 P:(DE-2719)2810591 |b 14 |
| 700 | 1 | _ | |a Stefanis, Leonidas |b 15 |
| 700 | 1 | _ | |a Gasser, Thomas |0 P:(DE-2719)2320009 |b 16 |e Last author |
| 773 | _ | _ | |a 10.1002/mds.28534 |g Vol. 36, no. 7, p. 1624 - 1633 |0 PERI:(DE-600)2041249-6 |n 7 |p 1624 - 1633 |t Movement disorders |v 36 |y 2021 |x 1531-8257 |
| 856 | 4 | _ | |u https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28534 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/155632/files/DZNE-2021-00800.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/155632/files/DZNE-2021-00800.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:155632 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9001971 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2812850 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)9000366 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2812657 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2351249 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 14 |6 P:(DE-2719)2810591 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2320009 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 1 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-345 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Population Studies and Genetics |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-342 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Disease Mechanisms and Model Systems |x 1 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 |0 LIC:(DE-HGF)CCBYNC4 |2 HGFVOC |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-11 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOVEMENT DISORD : 2021 |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-11 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-11 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOVEMENT DISORD : 2021 |d 2022-11-11 |
| 920 | 1 | _ | |0 I:(DE-2719)1410001 |k AG Zweckstetter |l Structural Biology in Dementia |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000055 |k AG Berg ; AG Berg |l Parkinson's Disease Genetics |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser 1 |l Parkinson Genetics |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1410001 |
| 980 | _ | _ | |a I:(DE-2719)5000055 |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|